Document is current
Any future updates will be listed below
-
Authors
Jenkins, David A.
Hussein, Humaira http://orcid.org/0000-0003-4308-9423
Martina, Reynaldo
Dequen-O’Byrne, Pascale
Abrams, Keith R.
Bujkiewicz, Sylwia
- License Information
-
More Information
Article History
Received: 8 April 2021
Accepted: 7 September 2021
First Online: 9 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: SB has served as a paid consultant, providing methodological advice, to NICE and Roche, and has received research funding from European Federation of Pharmaceutical Industries & Associations (EFPIA) and Johnson & Johnson.KRA has served as a paid consultant, providing methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sano_ and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.All other authors declare that they have no competing interests.
